IXLAYER
Q2 2026 Quarterly Account Review
Review period: April 1 through June 30, 2026
Probable legal name: IX Layer Inc.
Headquarters: San Francisco, California
Review status: Preliminary, pending USPS account data and legal-name validation
1. Executive Account Summary
IXLAYER is a cloud-based healthcare technology company that operates direct-to-patient healthcare programs for biopharmaceutical companies and other healthcare organizations. Its platform connects patients with telehealth, laboratory testing, benefits verification, payment services, prescription fulfillment, pharmacy pickup or home delivery, and other care services. The company states that its technology has supported more than four million patient-care journeys.
The company’s operating model can create several physical-mail and parcel streams even though its primary product is digital:
- At-home diagnostic test kits sent to patients.
- Patient specimen kits returned to laboratories.
- Replacement or incomplete test kits.
- Printed collection instructions and program materials.
- Medication delivery coordinated through pharmacy partners.
- Patient communications and compliance notices.
- Clinical-program launch materials.
- Employee and corporate parcels.
- Equipment or materials sent to partner laboratories and healthcare providers.
IXLAYER may coordinate the technology and patient experience without physically warehousing or mailing every item. Laboratories, pharmacies, manufacturers, fulfillment providers, biopharma clients, and health plans may control the actual labels, postage accounts, return addresses, and carrier contracts.
The most relevant Q2 2026 developments were:
- Appointment of Helmut Osorio as general manager to expand direct-to-patient programs for biopharma.
- Launch of Informed Pain Care in collaboration with Vertex Pharmaceuticals.
- Expansion of IXLAYER’s platform into a new acute-pain treatment pathway with telehealth evaluation, pharmacy fulfillment, home delivery, and local pickup.
- Continued focus on connecting awareness campaigns to testing, clinical evaluation, prescriptions, and treatment.
- No verified Q2 announcement of a new warehouse, fulfillment center, carrier agreement, acquisition, or funding round.
On May 27, IXLAYER appointed Helmut Osorio as general manager. The company said he would lead growth in direct-to-patient biopharma programs and brought experience from Regeneron, Pfizer, Purdue Pharma, and healthcare commercialization consulting.
On June 5, IXLAYER launched Informed Pain Care with Vertex Pharmaceuticals. The nationwide platform connects eligible acute-pain patients with licensed clinicians and, when appropriate, prescription treatment, including local pharmacy pickup or delivery.
Preliminary USPS assessment: The most meaningful USPS opportunity is likely not routine corporate-office shipping. It is the distributed patient-fulfillment network supporting at-home laboratory kits, specimen returns, replacement kits, educational materials, and healthcare-program operations. USPS must identify which laboratories, pharmacies, manufacturers, and fulfillment partners physically ship items generated by IXLAYER programs.
2. Quarterly Performance Comparison
USPS account performance
| Metric | Q2 2026 | Q1 2026 | Q2 2025 | Change |
|---|---|---|---|---|
| USPS revenue | Unavailable | Unavailable | Unavailable | Not calculable |
| Total mail and package volume | Unavailable | Unavailable | Unavailable | Not calculable |
| Average revenue per piece | Unavailable | Unavailable | Unavailable | Not calculable |
| Ground Advantage volume | Unavailable | Unavailable | Unavailable | Not calculable |
| Priority Mail volume | Unavailable | Unavailable | Unavailable | Not calculable |
| Outbound test-kit volume | Unavailable | Unavailable | Unavailable | Not calculable |
| Returned specimen-kit volume | Unavailable | Unavailable | Unavailable | Not calculable |
| Replacement-kit volume | Unavailable | Unavailable | Unavailable | Not calculable |
| Prescription-delivery volume | Unavailable | Unavailable | Unavailable | Not calculable |
| USPS product mix | Unavailable | Unavailable | Unavailable | Not calculable |
Average revenue per package should be calculated as:
USPS revenue ÷ USPS package volume
For laboratory programs, additional measures should include:
- Outbound kits per patient enrolled.
- Percentage of kits successfully returned.
- Average days from kit delivery to specimen return.
- Number of expired, damaged, lost, or unusable kits.
- Replacement-kit rate.
- Revenue per completed patient journey.
- USPS share by laboratory or fulfillment origin.
- Cost per completed test rather than only cost per outbound package.
The Project spreadsheet and related partner-account records are required to complete:
- Q2 2026 versus Q1 2026 revenue and volume.
- Q2 2026 versus Q2 2025 revenue and volume.
- Product-level percentage changes.
- Average revenue per package.
- Outbound versus inbound specimen activity.
- Revenue by laboratory, pharmacy, and fulfillment partner.
- Domestic versus international activity.
- Account engagement and pricing performance.
Verified public operating profile
| Operating element | Publicly stated information |
|---|---|
| Primary business | Direct-to-patient healthcare technology |
| Legal identity shown publicly | IX Layer Inc. |
| West Coast office | 447 Sutter Street, Suite 405, PMB 53, San Francisco |
| East Coast office | 222 Broadway, 22nd Floor, New York |
| Core services | Telehealth, lab testing, prescription fulfillment, benefits verification, payments and connected care |
| Patient-care scale | More than four million patient journeys |
| At-home testing | Self-collection kits can include saliva, blood, urine and fecal samples |
| Prescription fulfillment | Retail and specialty pharmacy dispensing, home delivery or local pickup |
| Physical fulfillment ownership | Not publicly disclosed |
3. Important Changes and Trends
Expansion into acute-pain care
Informed Pain Care adds an acute-pain program to IXLAYER’s platform. Patients complete digital intake, connect with licensed clinicians, and may receive treatment through a local pharmacy or delivery.
Potential USPS significance: The program may generate medication, clinical materials, patient instructions, or replacement communications. However, pharmacy partners rather than IXLAYER may control medication delivery, and some prescriptions may be collected locally rather than shipped.
Increased commercial leadership
The appointment of Helmut Osorio indicates a deliberate effort to expand pharmaceutical-company adoption of direct-to-patient programs. IXLAYER cited his experience in product launches, market access, marketing, and commercialization.
Potential USPS significance: New biopharma programs may create additional kit, specimen-return, education, or prescription-fulfillment activity. USPS should seek advance visibility into planned program launches instead of waiting until volume is already assigned to laboratories or fulfillment contractors.
Physical test kits remain part of the platform
IXLAYER’s ixEngage platform supports turnkey at-home collection kits for saliva, blood, urine, and fecal samples through laboratory partners. It also supports mobile phlebotomy and patient-service-center testing.
Potential USPS significance: Each at-home testing journey may require:
- An outbound collection kit.
- An inbound biological specimen.
- A replacement kit if the first is damaged, lost, incomplete, or unusable.
- Additional printed instructions or follow-up materials.
The shipping profile differs substantially by specimen type, packaging, temperature requirements, and laboratory destination.
Kit-return performance is operationally important
In a previously reported L.A. Care program, more than 70,000 at-home diagnostic kits were distributed, with a reported test-return rate of 20% to 25%. Although this program predates Q2 2026 and should not be treated as current-quarter volume, it demonstrates that IXLAYER-supported programs can involve large outbound-kit campaigns and thousands of inbound returns.
USPS significance: The key commercial measure is not simply the number of kits mailed. It is the number of patients who receive, complete, and successfully return usable specimens.
Home delivery is part of the patient choice model
IXLAYER’s prescription-fulfillment services include retail and specialty dispensing, nationwide home delivery, and local pickup.
Potential USPS significance: USPS may have an opportunity with eligible nonrestricted pharmacy shipments, patient materials, and supporting fulfillment. Medication carrier selection is likely controlled by licensed pharmacy partners and must be reviewed separately.
4. Relevant Company Developments
May 27, 2026: Helmut Osorio appointed general manager
IXLAYER appointed Helmut Osorio to accelerate direct-to-patient growth with biopharmaceutical clients. The company said he would report to co-founder and CEO Pouria Sanae.
USPS analysis: This creates a new senior stakeholder whose responsibilities may include launching programs that produce physical test kits, patient materials, and pharmacy shipments. USPS should position itself as a scalable fulfillment and returns partner during program design.
June 5, 2026: Informed Pain Care launched
IXLAYER and Vertex Pharmaceuticals launched a nationwide platform providing telehealth evaluation and access to acute-pain treatment options. The service supports insurance and self-pay pathways and allows pharmacy pickup or delivery.
USPS analysis: The initial shipping opportunity may be limited if most patients use local pickup. The account team should ask whether any medication, printed materials, onboarding kits, or service-recovery items are delivered to patients.
Q2 2026: Continued emphasis on integrated direct-to-patient care
IXLAYER continued positioning its platform as a connection among patient intake, clinical care, testing, prescriptions, payment, benefits verification, and follow-up.
USPS analysis: USPS should avoid treating IXLAYER as only a technology-office account. Its commercial value lies in the physical fulfillment generated across partner programs.
No major Q2 logistics expansion verified
No reliable Q2 source identified:
- A company-operated warehouse opening.
- A new fulfillment center.
- A USPS or competing-carrier contract.
- An acquisition or merger.
- A funding transaction.
- A laboratory acquisition.
- A pharmacy acquisition.
- A new corporate-office relocation.
USPS analysis: Internal postage data and customer discovery are necessary to determine whether Q2 activity increased.
5. Potential USPS Impact
Ground Advantage
Ground Advantage may be suitable for:
- Nonurgent outbound collection kits.
- Printed patient materials.
- Replacement kit components.
- Program launch materials.
- Nonregulated equipment.
- Routine corporate and employee parcels.
Ground Advantage may not be appropriate for time-sensitive specimens or packages requiring air transportation, temperature control, or specialized biological-substance handling.
Priority Mail
Priority Mail may support:
- Time-sensitive diagnostic kits.
- Replacement kits needed before enrollment windows close.
- Patient kits associated with treatment decisions.
- Clinical-program launch materials.
- Laboratory supplies.
- Urgent service-recovery shipments.
- Selected inbound specimens where packaging and mailability requirements allow.
Priority Mail Express
Potential uses include:
- Specimens with short stability periods.
- Urgent replacement kits.
- Clinical-trial or treatment-decision deadlines.
- Critical program supplies.
- Time-sensitive healthcare documentation.
Actual eligibility depends on specimen classification, packaging, laboratory instructions, and postal regulations.
Biological specimen returns
IXLAYER programs can include blood, saliva, urine, or fecal sample collection.
USPS must determine:
- Exact specimen classification.
- Whether samples are exempt human specimens or regulated biological substances.
- Required packaging and markings.
- Liquid containment and absorbent-material requirements.
- Temperature and stability windows.
- Air and surface eligibility.
- Return-label expiration.
- Laboratory receiving hours.
- Weekend and holiday restrictions.
- Damaged or leaking package procedures.
No mailability conclusion should be made without reviewing the specific collection device and laboratory protocol.
Returns and reverse logistics
The principal reverse-logistics stream is likely the return of collected specimens rather than traditional merchandise returns.
Potential USPS opportunities include:
- Prepaid return labels included in kits.
- QR-code or printerless return options where clinically practical.
- Pre-addressed return packaging.
- Patient drop-off instructions.
- Acceptance and tracking scans.
- Automated reminders after kit delivery.
- Laboratory receipt confirmation.
- Reporting by program, laboratory, and patient cohort.
Pharmacy fulfillment
IXLAYER supports home delivery and local pharmacy pickup.
USPS should identify:
- Licensed pharmacy partners.
- Which products are eligible for postal delivery.
- Temperature-control requirements.
- controlled-substance exclusions.
- signature requirements.
- packaging and privacy controls.
- return-to-pharmacy procedures.
- pharmacy origin ZIP Codes.
- Existing carriers and service commitments.
Pickup and induction
Because physical fulfillment may occur through partner laboratories, pharmacies, kit manufacturers, or third-party logistics providers, USPS should map:
- Every shipping origin.
- Every specimen-return destination.
- Postage-paying entity.
- Current carrier.
- Daily and campaign volume.
- Pickup schedule.
- Weekend operations.
- Acceptance scanning.
- Returns processing.
- Label and API integration.
- Responsible USPS sales territory.
6. Opportunities
1. Build a complete partner-network map
Identify all:
- Clinical laboratories.
- Kit manufacturers.
- Fulfillment providers.
- Pharmacies.
- biopharma clients.
- health-plan clients.
- return laboratories.
- postage-paying entities.
2. Measure program-level USPS value
USPS revenue may appear under partner accounts rather than IX Layer Inc. Create a combined view showing volume generated by IXLAYER-supported programs.
3. Informed Pain Care discovery
Determine whether the Vertex collaboration creates:
- Medication deliveries.
- Patient starter materials.
- Printed education.
- service-recovery shipments.
- pharmacy parcels.
- provider materials.
4. Improve specimen-return rates
Evaluate how postal design could reduce incomplete patient journeys through:
- Easier return instructions.
- prepaid packaging.
- tracking notifications.
- address validation.
- convenient drop-off.
- delivery and return reminders.
- laboratory-receipt reporting.
5. Standardize kit fulfillment
Create repeatable USPS service rules based on:
- Kit type.
- specimen type.
- package weight.
- stability window.
- destination laboratory.
- urgency.
- regulatory classification.
6. Support large health-plan campaigns
Historical IXLAYER-supported programs have involved tens of thousands of test kits.
USPS could support:
- Advance forecasts.
- staged induction.
- address hygiene.
- destination-entry analysis.
- return-volume planning.
- campaign performance reporting.
7. Integrate postal data into the platform
Explore whether tracking, delivery, return acceptance, and laboratory receipt events can be connected to IXLAYER’s patient-engagement workflows.
8. Replace failed kits quickly
Develop service standards for:
- Lost outbound kits.
- damaged kits.
- expired kits.
- incomplete samples.
- laboratory-rejected specimens.
- incorrect addresses.
9. Corporate-office account cleanup
Validate accounts under:
- IXLAYER.
- ixlayer.
- IX Layer Inc.
- San Francisco office.
- New York office.
- Legacy laboratory or program names.
7. Risks and Concerns
- USPS revenue and package-volume data are unavailable.
- IXLAYER may not physically fulfill its programs.
- Laboratories, pharmacies, manufacturers, or clients may control postage and carriers.
- Physical volume may be fragmented across many USPS territories and accounts.
- Biological specimens have strict packaging and mailability requirements.
- Some specimens may have short stability windows.
- Medication deliveries may require licensed pharmacy processes or specialized carriers.
- Local pharmacy pickup may reduce parcel opportunity.
- Patient health information requires strong privacy controls.
- Failed deliveries can delay diagnosis or treatment.
- Returned specimen kits may be unusable if delayed or improperly prepared.
- Growth in digital services does not automatically produce proportional postal growth.
- Current pricing, agreements, service issues, origins, and prior commitments remain unknown.
- The San Francisco address is presented as a corporate office and private mailbox, not a verified fulfillment location.
8. Customer Questions
- Is IX Layer Inc. the correct USPS legal account name?
- Which IXLAYER-supported programs currently generate physical kits or patient parcels?
- Which laboratories and fulfillment providers ship the kits?
- Who purchases postage for outbound kits?
- Who purchases postage for specimen returns?
- What were Q2 2026 USPS revenue and package volume compared with Q1 2026 and Q2 2025?
- How much IXLAYER-generated USPS revenue appears under partner accounts?
- Which carriers currently handle:
- Outbound test kits?
- Returned specimens?
- Replacement kits?
- Patient materials?
- Prescription delivery?
- What specimen types are mailed?
- What are the average package weights, dimensions, and zones?
- What percentage of kits is successfully returned?
- What is the average time from kit delivery to specimen return?
- How many kits require replacement?
- What are the leading reasons for replacement?
- Which laboratories experience weekend or delivery-cutoff problems?
- Are return labels included in each kit?
- Do labels expire?
- Can patients use printerless or QR-code returns?
- Which physical shipments are associated with Informed Pain Care?
- Which pharmacy partners offer home delivery?
- Are there known USPS pickup, acceptance, tracking, damage, billing, or delivery issues?
- Can USPS tracking events be integrated into IXLAYER’s patient platform?
- When does any current USPS pricing agreement expire?
- Which commitments from the prior QAR remain open?
9. Recommended Actions
USPS actions
- Retrieve Q2 2026, Q1 2026, and Q2 2025 USPS revenue and volume.
- Validate the legal entity, Salesforce record, CRIDs, permits, and payment accounts.
- Build a parent-partner account map for laboratories, pharmacies, fulfillment providers, and biopharma programs.
- Obtain program-level outbound and return shipment data.
- Calculate average revenue per package.
- Measure kit-return and replacement rates.
- Review Informed Pain Care for physical fulfillment opportunities.
- Conduct a specimen mailability and packaging review for each kit type.
- Analyze Ground Advantage for nonurgent kits and materials.
- Analyze Priority Mail and Priority Mail Express for time-sensitive eligible kits and specimens.
- Review prepaid and printerless specimen-return options.
- Evaluate address-quality and patient-delivery exception data.
- Explore shipment-event integration with IXLAYER’s technology platform.
- Develop advance forecasts for major biopharma and health-plan campaigns.
- Confirm pricing-agreement expiration and renewal requirements.
- Document service issues, previous commitments, responsible parties, and due dates.
Recommended customer follow-up
Schedule a QAR involving:
- IXLAYER commercial leadership.
- Platform operations.
- Laboratory services.
- Prescription-fulfillment leadership.
- Patient experience.
- Compliance and privacy.
- Product and engineering.
- Finance and procurement.
- Participating laboratories.
- Pharmacy and fulfillment partners.
The first discussion should focus on mapping physical fulfillment, measuring network-level USPS value, reviewing Informed Pain Care, improving kit-return rates, and integrating postal tracking into patient workflows.
10. Salesforce-Ready Account Update
Q2 2026 QAR: IXLAYER, publicly identified as IX Layer Inc., operates a cloud-based direct-to-patient healthcare platform connecting patients with telehealth, laboratory testing, benefits verification, prescription fulfillment, pharmacy pickup or home delivery, and connected-care services. The company states that its platform has supported more than four million patient-care journeys.
During Q2, IXLAYER appointed Helmut Osorio as general manager to accelerate biopharma growth and launched Informed Pain Care with Vertex Pharmaceuticals. The new nationwide acute-pain platform supports clinician evaluation and access to prescription treatment through pharmacy pickup or delivery.
Potential USPS opportunities include outbound at-home test kits, inbound specimen returns, replacement kits, patient materials, Ground Advantage for nonurgent eligible shipments, Priority Mail for time-sensitive kits, and integration of USPS delivery and return tracking into patient workflows.
Risks: USPS account data and carrier allocation were unavailable. IXLAYER may coordinate rather than physically fulfill shipments, with laboratories, pharmacies, manufacturers, and fulfillment providers controlling postage. Biological specimens and prescription products require program-specific mailability, privacy, packaging, and timing review.
Next steps: Validate the legal account, retrieve quarterly USPS performance, identify all laboratory and pharmacy partners, map outbound and return flows, quantify kit-return rates, review Informed Pain Care fulfillment, complete specimen-mailability analysis, and schedule a network-level logistics review.
Follow-up date: Not provided.
11. Information Required to Finalize the QAR
- Correct legal entity and Salesforce account ID.
- Q2 2026 USPS revenue and package volume.
- Q1 2026 USPS revenue and package volume.
- Q2 2025 USPS revenue and package volume.
- Average revenue per package.
- USPS product-level activity.
- Active healthcare programs.
- Laboratory and pharmacy partners.
- Fulfillment providers and origins.
- Postage-paying entities.
- Current carrier mix.
- Outbound test-kit volume.
- Returned specimen volume.
- Kit-return percentage.
- Replacement-kit volume.
- Package weights, dimensions, zones, and values.
- Specimen classifications and stability requirements.
- Prescription-delivery volume.
- Pickup arrangements.
- Tracking integration.
- Current pricing agreement.
- Agreement expiration date.
- Known service issues.
- Previous commitments.
- Open opportunities.
- Last meeting and QAR dates.
- Next action and follow-up date.
12. Sources
- IXLAYER, May 27, 2026: Appointment of Helmut Osorio as general manager to accelerate direct-to-patient growth for biopharma.
- IXLAYER, June 5, 2026: Launch of Informed Pain Care in collaboration with Vertex Pharmaceuticals.
- PR Newswire, June 5, 2026: Independent distribution of the Informed Pain Care launch announcement and platform details.
- IXLAYER corporate platform, reviewed June 30, 2026: Telehealth, laboratory testing, prescription fulfillment, benefits verification, connected care, home delivery, and local pharmacy pickup.
- IXLAYER ixEngage platform, reviewed June 30, 2026: At-home saliva, blood, urine, and fecal collection kits, laboratory integration, e-prescribing, specialty pharmacy dispensing, and home delivery.
- IXLAYER and L.A. Care, June 18, 2025: Historical example involving more than 70,000 distributed diagnostic kits and a 20% to 25% return rate. Used only as operating context, not as Q2 2026 performance.
- IXLAYER contact information, reviewed June 30, 2026: IX Layer Inc. San Francisco and New York corporate-office addresses.
